Company: CMND
Filing Date: 2025-01-22
Form Type: POS AM
Source: 0001213900-25-005519
Chunk: 17

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: POS AM
Chunk 17
---
 
 become available;                                  |

| ● | the beneficial characteristics, safety, efficacy and                                                                               
 therapeutic effects of our future product candidates, as well as the potential healthcare costs saved through utilizing our future 
 product candidates;                                                                                                                |

| ● | the ability of our future product candidates to address    
 needs not currently addressed by the psychedelic industry; |

| ● | the ability of our future product candidates to address    
 needs not currently addressed by the psychedelic industry; |

| ● | our ability to obtain and maintain regulatory approval 
 of our future product candidates;                      |

| ● | our plans relating to the further development of our                                         
 future product candidates, including additional disease states or indications we may pursue; |

| ● | existing regulations and regulatory developments in 
 the United States and other jurisdictions;          |

| ● | our plans and ability to obtain or protect intellectual                                                                             
 property rights, including extensions of patent terms where available and our ability to avoid infringing the intellectual property 
 rights of others;                                                                                                                   |

| ● | the ability of our management team to oversee our drug 
 research programs;                                     |

| ● | the need to hire additional personnel and our ability 
 to attract and retain such personnel;                 |

| ● | our estimates regarding expenses, future revenue, capital 
 requirements and needs for additional financing;          |

| ● | our dependence on third parties; |

| ● | our ability to compete with other companies who offer                                 
 products that address similar issues that our future product candidates will address; |

| ● | our financial performance; |

| ● | the period over which we estimate                                                                                                     
 our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; |

| ● | our ability to generate revenue and profit margin under      
 our anticipated contracts which is subject to certain risks; |

<div align='center'>6</div>

| ● | difficulties in our partners’ ability to recruit                                                                                
 and retain qualified physicians and other healthcare professionals, and enforce our non-compete agreements with our physicians; |

| ● | our ability to restructure our operations to comply 
 with future changes in government regulation;       |

| ● | security, political and economic instability in                                                      
 the Middle East that could harm our business, including due to the security situation in Israel; and |

| ● | those factors referred to in our 2024 Annual Report                                                            
 incorporated by reference herein in “Item 3. Key Information – D. Risk Factors,” “Item 4. Information on       
 the Company,” and “